Skip to content
Clinical Trials – home
ItalyBack to Italy

Clinical trials in Reggio Emilia – page 48

731 clinical trials in Reggio Emilia, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Reggio Emilia at a glance
731
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

731 trials in Reggio Emilia

Open in trial search

Study of daily low-dose temozolomide in patients with advanced neuroendocrine tumors (NETs) who are not eligible for standard treatments due to their health condition

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Temozolomide
  • Sponsor:Istituto Europeo Di Oncologia S.r.l.

Study of Datopotamab Deruxtecan and Durvalumab for Adults with Untreated Triple-Negative or Hormone Receptor-Low/HER2-Negative Breast Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:AstraZeneca AB

Asthma

Not recruiting

Study on the Effects of Dexpramipexole for Adolescents and Adults with Severe Eosinophilic Asthma

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Budesonide
  • Sponsor:Areteia Therapeutics Inc.

Study Comparing Camizestrant and Palbociclib with Anastrozole and Palbociclib for Patients with ER-Positive, HER2-Negative Advanced Breast Cancer Without Prior Treatment

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:AstraZeneca AB

Study on Atezolizumab and Trastuzumab Emtansine for Patients with HER2-Positive Breast Cancer at High Risk of Recurrence After Preoperative Therapy

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Breast cancer

Not recruiting

Study on Olaparib for Patients with High-Risk HER2-Negative Breast Cancer and BRCA1/2 Mutations After Chemotherapy

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Olaparib
  • Sponsor:AstraZeneca AB

Myelofibrosis

Not recruiting

Study of Imetelstat Compared to Drug Combination for Treating Intermediate-2 or High-Risk Myelofibrosis in Patients Not Responding to JAK-Inhibitor Treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Alkylating agents
  • Sponsor:Geron Corp.

Renal cell carcinoma

Not recruiting

Study of V940 and Pembrolizumab for Patients with Renal Cell Carcinoma After Surgery

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:MRNA-4157
  • Sponsor:Merck Sharp & Dohme LLC

HIV infection

Not recruiting

Study on Budigalimab and ABBV-382 for People with HIV on Stable Antiretroviral Therapy

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Budigalimab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Neoplasm malignant+1

Not recruiting

Study on the Safety and Tolerability of Spartalizumab for Patients with Advanced Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Canakinumab
  • Sponsor:Novartis Pharma AG

Study of OP-1250 for Treating Advanced or Metastatic ER+, HER2- Breast Cancer in Patients After Endocrine and CDK4/6 Inhibitor Therapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Olema Pharmaceuticals Inc.

Study of Azenosertib (ZN-c3) for Women with Recurrent or Persistent Uterine Serous Carcinoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Aprepitant
  • Sponsor:K-Group Beta Inc.

Other cities in Italy

The busiest research cities in the country

All 232 cities in Italy

Clinical research in Reggio Emilia

What the registry says about research in the country

01 Oncology - Solid Tumors

Innovative clinical trials focusing on metastatic colorectal cancer, non-small cell lung cancer, and gastric cancer. Research evaluates novel therapeutic approaches including targeted therapies and immunotherapy combinations.

  • Colorectal Cancer Treatments
  • Lung Cancer Therapies
  • Gastrointestinal Oncology

Studies include assessment of treatment efficacy and novel drug combinations for advanced stage cancers.

02 Hematologic Malignancies

Groundbreaking research in B-cell lymphomas and chronic myeloid leukemia. Studies evaluate innovative treatment approaches including targeted therapies and combination protocols.

  • Lymphoma Treatments
  • Leukemia Therapies
  • Novel Drug Combinations

Focus on improving patient outcomes through personalized treatment approaches.

03 Autoimmune Conditions

Clinical trials investigating treatments for Sjögren's Syndrome and other inflammatory conditions. Research aims to evaluate long-term safety and efficacy of novel therapeutic agents.

  • Inflammatory Disorders
  • Autoimmune Diseases
  • Novel Therapeutics

Studies focus on developing safer and more effective treatment options for patients.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.